Synonyms: CDP-323 | CDP323
Compound class:
Synthetic organic
Comment: Zaurategrast (CDP-323) is a small molecule inhibitor of α4-containing integrin complexes that was developed by Celltech [3]. It was intended as a new oral drug treatment for multiple sclerosis [2]. Zaurategrast has the same mechanism of action as the approved MS therapeutic natalizumab. Zaurategrast is an ester prodrug whose active entity is CT7758 [1].
|
|
No information available. |
Summary of Clinical Use ![]() |
Clinical development appears to have been terminated due to lack of demonstrable efficacy. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00484536 | Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323 | Phase 2 Interventional | UCB Pharma | ||
NCT00726648 | CDP323 Biomarker Study | Phase 1/Phase 2 Interventional | UCB Pharma | 4 |